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Figure 1-1 German incidence rates (raw rates and age adjusted) and mortalility rates (raw rates and age 
adjusted) for men (blue) and women (red); data according by the Robert-Koch-Institute, Berlin 
 
1.2 Etiology and risk factors 
Generally, the risk for developing melanoma depends on two major principles: 
Firstly on environmental factors and, secondly on intrinsic factors. 
Exposure to UV-radiation is the most important exogenic risk factor for the 
development of malignant melanoma. The risk to develop malignant melanoma 
is mostly acquired during childhood and adolescence (before the age of 20 years, 
mainly in the first decade of life) due to an UV-induced activation of the 
melanocytic system. This activations leads to the development of benign 
melanocytic lesions known as nevi: 
 The risk to develop malignant melanoma increases with by the total 
number of melanocytic nevi over the entire body.[7] 
 The type of nevi (atypical melanocytic nevi, dysplastic nevi) are additional 
independent risk factors for melanoma.[7, 8] 
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 People with skin type I according to Fitzpatrick (fair skin, red or blond hair, 
tendency to freckle, blue eyes) are more susceptible to develop melanoma 
than more darkly pigmented people. 
 Chronic sun exposure associated with increased incidence of lentigo 
maligna melanoma, while intermittent sun exposure is associated with 
superficial and nodular melanoma.[8] 
 Familial incidence of melanoma (two or more first degree relatives with the 
mutations in CDKN2A are detectable diseases [8, 9]) is evident in about 
5%-10% of melanoma patients.  
Their lifetime risk to develop melanoma is estimated to reach 67%.[10] 
Interestingly, most of the patients detect a suspicious lesion themselves. Only 
selected individuals, for example, such with a dysplastic nevus syndrome, are 
regularly screened by dermatologists. In such cases digital dermatoscopy allows 
analyzing and documenting pigmented lesions reliably. Often diagnostic clues 
are exclusively detectable using this technique. Experts reach an increase of 20% 
in the diagnostic sensitivity in contrast to conventional clinical observation. They 
achieve a sensitivity of about 90% and specify of approximately 80%.[11] Up to 
date systems are computer based and include automated diagnostic algorithms. 
1.3 Genetic factors 
Genetic aberrations in melanoma frequently affect cell signaling pathways that 
play an essential role in normal melanocyte biology. Specific aberrations in 
melanoma signaling provide treatment targets for molecular therapies. Promising 
treatment targets are for example genes upregulated in cancer, yet not in normal 
tissues, or genes with frequent oncogenic mutations that can be specifically 
targeted. 
1.3.1 BRAF 
Mutations in the BRAF gene were firstly described by the Sanger Institute in 
2002.[12] It is the most commonly mutated oncogene identified in melanoma 
(approximately 50%) to date and an upstream mediator of the mitogen-activated 
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protein kinase (MAPK) pathway.[12, 13] In over 80% of the patients this activating 
mutation results from a substitution of glutamic acid by valine at amino acid 600 
(V600E mutation) with most of the remainder consisting of an alternate 
substitution (lysine for valine) at the V600 locus (V to K); however different other 
mutations are known meanwhile (Table 1-1). 
 
Table 1-1 Frequency of BRAF mutations [15] 
V600E 97.3% 
V600K 1.0% 
K601E 0.4% 
G463A 0.4% 
D594G 0.3% 
V600R 0.3% 
L597V 0.2% 
 
Increased activation of the MAPK pathway is implicated in melanoma tumor 
genesis and is enhanced in advanced-stage melanoma.[13] Generally, BRAF-
mutated melanomas occur in younger aged patients on skin without signs of solar 
damage and affect less frequently the head and neck area. Therefore, BRAF-
mutated melanomas seem to arise early in life at low cumulative UV doses, 
whereas melanomas without BRAF mutations seem to require accumulation of 
high UV doses over time.[14] 
1.3.2 RAS 
Three types of human RAS proto-oncogenes (H-RAS, K-RAS, and N-RAS) have 
been described. N-RAS mutations are frequent in myeloid leukemias and 
melanomas.[16] Up to 24% of malignant melanoma have activated RAS gene 
mutations mutations.[17] N-RAS mutations are detectable more often in 
melanomas arising from chronic sun exposure and are more common in lentigo 
maligna melanoma and nodular melanoma than in superficial spreading and 
acrolentiginous melanoma.[16] RAS mutations are also present in 10% of 
common acquired nevi and 28% - 56% of congenital nevi.[16] 
12 
 
1.3.3 KIT 
C-KIT is a protein that acts as a fundamental growth factor receptor in epidermal 
melanocytes and is important for differentiation and migration of melanocytic cells 
during embryonic development.[18, 19] The receptor tyrosine kinase KIT acts on 
a downstream signaling cascade leading to key intracellular signals controlling 
cellular proliferation and survival.[20] KIT aberrations were identified in 
melanomas of mucosal membranes, acral skin and skin with chronic sun-induced 
damage. KIT aberrations are present in up to 39%, 36%, 26% respectively.[19] 
1.4 Management of the Primary Melanoma 
Ideally, lesions that are clinically suspicious for melanoma ought to experience 
an excisional biopsy with slender boundaries (such as 2 mm).[21] Although there 
is proof that an incisional biopsy does not influence survival,[22] this methodology 
should ought to be a special case and kept for situations where the tumor is too 
big to be extracted, or when it is unrealistic to perform a complete excision (for 
example; the nail unit). The excised sample should be interpreted by an 
experienced dermatopathologist acquainted with the microscopic diagnosis of 
melanocytic lesions. 
Following histologic diagnosis, the primary melanoma site should be re-excised 
with a proper margin determined by the Breslow's depth. The basis for extending 
the excisional margins is the capability of melanoma cells to relocate far from the 
tumor origin. Melanoma may amplify more extensive or more profound than at 
first obvious. The major aim is to avert neighborhood repeat or constant infection. 
Present recommendations are extraction margins of 0.5 cm for in situ melanoma, 
1 cm for melanoma up to 2 mm tumor thickness and 2 cm for melanomas with 
more than 2 mm tumor thickness.[1, 23] Margins of excision are also limited by 
surgically difficult anatomic sites such as the face, the mucous membranes or the 
distal extremities, and, in numerous examples, an individualized surgical 
methodology must be undertaken. Typically, lentigo maligna melanoma in the 
face requires narrower safety margins, and micrographic control of extraction 
margins may be included so as to safe tissue. Surgical methodologies ought to 
respect the structure of the face as well as aesthetic and functional aspects. 
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Lentiginous acral and mucosal melanomas are regularly ineffectively 
characterized and multifocal with inconsistencies between the clinically visible 
and histopathologic margins. Local recurrences are more common in these sorts 
of melanoma. In this manner, elimination can be achieved with expanded safety 
margins (at least 1cm) or by narrow margins with micrographic control.[24] 
Likewise, micrographic surgery is indicated for subungual melanoma in order to 
assure tumor-free resection margins and to achieve better cosmetic and 
functional results by avoiding amputation.[25] 
1.5 Management of the Regional Metastatic Melanoma 
In about 70% of the cases metastatic spread of melanoma is primarily regional 
and confined to the site of the primary melanoma and its draining lymph nodes. 
Metastasis may manifest as a clinically occult lymph node micro metastasis, as 
a rapidly growing clinically evident macro metastasis, or as in-transit metastasis. 
Approximately 20% of patients with a cutaneous melanoma that is >1 mm in 
depth plus no evidence (clinically or radiologically) of detectable nodal disease at 
initial presentation show microscopic involvement.[26] On the premise of an 
assumed relocation of melanoma cells in an efficient manner towards the draining 
lymph node, surgical resection of territorial lymph nodes in all patients who 
suffered from intermediate and high-risk tumors was suggested in the 1980s and 
alluded to as 'elective lymph node dissection' (ELND). However, four multi-center 
randomized planned trials in patients with primary melanoma failed to 
demonstrate a survival benefit for patients treated with ELND plus wide re-
excision as compared to wide re-excision alone.[27-30] 
As a consequence, a less traumatic strategy to identify regional metastatic 
disease was presented, assigned as sentinel lymph node biopsy (SLNB).[31] 
SLNB is based on the finding that the cutaneous site of the melanoma drains to 
one or more lymph node basins and specially to one (or two yet once in a while 
more) lymph node, the sentinel node, which is the first site of deposition of 
metastatic cells. The draining lymph node basins for a given melanoma site and 
the estimate location of the sentinel node within that basin are identified and 
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marked on the overlying skin preoperatively during lymphoscintigraphy 
performed in the nuclear medicine suite. Intraoperatively mainly in conjunction 
with the wide local excision, technetium sulfur colloid and blue dye are injected 
into the skin encompassing the melanoma biopsy site. A small cut is made at the 
beforehand checked site overlying the sentinel node and visual inspection and a 
hand-held gamma counter are used to identify the 'hot, blue' sentinel node(s) 
which is selectively biopsied and inspected by serial sectioning using H&E stains 
joined with immunohistochemistry (S100, HMB45). If melanoma micro 
metastases are identified, a complete regional lymph node dissection is usually 
recommended. As the therapeutic benefit of complete lymphadenectomy after 
positive sentinel node has not been demonstrated in clinical trials, two large 
multicenter trials (MSLT-2, ADO-LNB1) are presently conducted comparing 
complete lymphadenectomy versus observation only in patients with lymph node 
micro metastasis. 
Sentinel lymph node biopsy followed by complete lymphadenectomy in case of 
positive nodes has meanwhile become a standard procedure in treatment and 
staging of primary cutaneous melanoma of 1 mm tumor thickness or more. 
Numerous publications identified the status of the sentinel lymph node as a strong 
prognostic factor for survival and recurrence, and the American Joint Committee 
on Cancer included it in the latest staging system for cutaneous melanoma.[32] 
Published in 2006 and 2014 the randomized Multicenter Selective 
Lymphadenectomy Trial (MSLT-1) confirmed the prognostic value of SLND, and 
found improved disease free survival for the SLND group, improved survival for 
SLND positive patients with complete lymphadenectomy as compared to patients 
developing macroscopic nodal metastasis in the control group, but no difference 
in overall survival.[33, 34]. 
If lymph node metastases are diagnosed clinically or by imaging techniques, 
complete lymph node dissection is considered standard therapy, which consists 
of an anatomically complete dissection of the involved nodal basin.[1] The extent 
of complete lymph node dissection is often modified according to the anatomic 
area of lymph node involvement. 
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1.6 Adjuvant Treatment of Melanoma 
Patients with thick (>2.0 mm) primary melanoma and/or regional lymph node 
metastases are at expanded danger of repeat and demise.[32] Current 
recommendations for patients with stage II (as showed by AJCC/UICC 
classification, yet negative nodes) melanoma are for adjuvant treatment with IFN 
or enlistment in a clinical trial.[1, 35] Patients with stage III melanoma regularly 
experience complete lymphadenectomy took after adjuvant treatment with IFN or 
enlistment in a clinical trial of adjuvant therapy.[1, 35] Over the last 25 years, 
adjuvant treatment for impending danger (stage II and IIIA) and high-hazard 
(stage IIIB and in addition resectable stage IV M1a, M1b) patients have stirred 
from systemic immunostimulants such as pharmacologic immunomodulators 
such as levamisole, or Bacillus Calmette-Guerin (BCG), Corynebacterium 
parvum and regional radiotherapy, to recombinant DNA-produced biologic agents 
such as antibodies, IFN-α, and granulocyte-macrophage colony-stimulating 
factor that have immunoregulatory function. 
Recently, first results from an EORTC trial comparing 10mg/kg Ipilimumab vs. 
placebo (1:1) in 951 patients with stage III disease were published.[36] After 2.7 
years of median follow up Ipilimumab significantly increased recurrence free 
survival for actively treated patients. However, the majority of the patients 
receiving Ipilimumab discontinued treatment because of side effects. 
 
1.7 Treatment of Metastatic Melanoma 
In previous decades median survival time was estimated to be approximately 8 
months (±2 months) for patients suffering from AJCC stage IV metastatic 
melanoma, and only ~10% of the patients survived more than 5 years from 
diagnosis of metastatic melanoma.[32] Currently, several agents are 
acknowledged for the treatment of patients with metastatic melanoma in the US: 
dacarbazine and high-dose IL-2 were registered in the late 70’s and 90’s. 
Ipilimumab, a CTLA-4 antibody was approved by the FDA in 2011, followed by 
the approval of Vemurafenib (BRAF-inhibitor 2011), Dabrafenib (BRAF-inhibitor 
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2013), Trametinib (MEK-inhibitor 2013) and the combination of Dabrafenib & 
Trametinib (2014). 
1.7.1 Chemotherapy 
Chemotherapy is still an accepted palliative treatment for stage IV metastatic 
disease and dacarbazine is the most broadly utilized sole chemotherapeutic 
agent for the treatment of metastatic melanoma.[37] Dacarbazine was initially 
reported to yield objective reactions for almost 25% of patients in older phase II 
trials, yet current trials in more rigorous, large-scale, supportive group settings 
have shown response rates of 5%-12%.[37] Unfortunately, most reactions to this 
agent and its oral analogue temozolomide are transient; only 1%-2% of patients 
accomplish a robust long-term response to chemotherapy.[37] Other 
chemotherapies that have been investigated incorporate fotemustine that has 
essentially enhanced the objective response rate (15.2% vs. 6.8%; p=0.043) and 
prolonged median overall survival, although non-significantly (7.3 months vs. 5.6 
months; p=0.067) comparing with dacarbazine in a phase III trial.[38] 
The antitumor activity of mixed chemotherapeutic agents has been assessed as 
an outcome of the increasingly frequently-held conviction that single agents are 
unlikely to enhance the result of patients with advanced metastatic 
melanoma.[37] Other polychemotherapies examined in phase III trials (for 
example, Dartmouth regimen: vinblastine/ cisplatin/ tamoxifen/ dacarbazine) 
have failed to exhibit a survival benefit compared with dacarbazine alone.[39] 
For patients who are not qualified for current investigational trials, chemotherapy 
with one of these agents remains a sensible palliative choice; for novel agents 
being tried in clinical trials, chemotherapy is an acknowledged comparator.[37] 
1.7.2 Interleukin-2 and other Immunotherapies 
High-dose recombinant IL-2 received its FDA approval in 1998 for the treatment 
of patients with metastatic melanoma. Objective response rates of up to 16% 
were seen in a group of phase II trials in patients (N=47) with metastatic 
melanoma exhibited for administrative audit. 
Single-agent therapy was managed utilizing the high-dose regimen of 600,000 
U/kg IL-2 at regular interval time of 8 hours for up to 14 doses in inpatient 
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cohorts.[40] barely 5% of the patients had long-term, durable complete reactions 
with IL-2, which has been taken as potential cure. However, this therapy has 
never shown to improve overall survival in a randomized phase III trial. 
In addition, IL-2 induced toxicity is severe [40] and normally requires intensive 
care.[41] Major dose-limiting toxicities include hemodynamic toxicity like 
hypotension, edema, weight gain, and decreased renal function as well as 
respiratory insufficiency, and neurotoxicity.[41] In contrast to the US, high-dose 
recombinant IL-2 has not been permitted in Europe. 
1.7.3 Bio-Chemotherapy 
Biochemotherapy is the combination of a chemotherapeutic schedule 
(polychemotherapy) and the addition of cytokines. In a survey of 41 randomized 
clinical trials of patients receiving several treatment schedules, including many 
biochemotherapy regimens, none of them enhanced progression-free survival or 
overall survival.[37] Furthermore, a meta-analysis including 18 trials and over 
2600 patients with metastatic melanoma proposed favorable position of 
biochemotherapy regarding objective response yet discovered no advantage in 
terms of overall survival (p=0.9).[42] 
 
1.8 Novel Therapies for Patients with Metastatic Melanoma 
A continuous improvement in understanding the tumor genesis and biology as 
well as the nature of immune antitumor response and regulation has led to the 
development of several novel sophisticated anticancer agents. Different methods 
to overcome tolerance include inhibition of oncogenic kinase pathways, blockade 
of inhibitory immune receptors and downregulation of anti-apoptotic proteins. 
1.8.1 Antibody Blockade of Cytotoxic T lymphocyte-associated Antigen 4 
Basically, a full activation of T-cells requires two major signals: First, an 
incitement through the T-cell receptor and additionally a Co-stimulatory signal 
regularly given by the binding of B7 on the antigen-presenting cell (such as 
dendritic cell) to CD28 on the T cell. Cytotoxic T lymphocyte associated antigen 
4 (CTLA4) is an inhibitory T-cell receptor and a homologue of CD28 that is 
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upregulated following T cell activation. The normal function of CTLA4 is to strive 
with CD28 to bind B7 and to downregulate T cell activation, acting as a usual 
“brake" by removing the costimulatory signal. The CTLA4-B7 interaction can be 
obstructed with an anti-CTLA4 monoclonal antibody (mAb), which has a greater 
liking for CTLA4 than B7. Accordingly, the inhibitory signal is prevented and the 
“brake" on T-cell activation released. 
Two fully human anti-CTLA4 antibodies were developed in melanoma: 
tremelimumab and ipilimumab. Target response rates of patients with metastatic 
melanoma treated with any of the two anti-CLTA4 antibodies as sole agent was 
quite similar (7%-10%).[43, 44] A randomized study in a phase III of 
chemotherapy (n=327) with dacarbazine or temozolomide in treatment-naive 
patients and tremelimumab (15 mg/kg administered once every 3 months, 
n=328), middle survival was longer (almost 12 months) in patients treated with 
tremelimumab contrasted with chemotherapy (barely 11 months).[43] However, 
the distinction was not factually noteworthy (hazard ratio chemotherapy/ 
tremelimumab 1.04; p=0.729), and the trial was stopped at the second interim 
analysis. 
Ipilimumab was likewise examined in a large phase III trial in patients with 
advanced melanoma.[44] Results of this randomized phase III trial for the mixture 
of Ipilimumab treatment versus gp100 vaccination, and versus single ipilmumab 
and gp100 vaccination have been published demonstrating an enhanced general 
survival of a median duration of 10 months in the ipilimumab arm and the 
combined arm, against 6.4 months in the vaccination alone arm. Although 
objective reaction rates were fairly low with 5.7% in the combined ipilimumab and 
vaccination arm, 10.9% in the ipilimumab alone arm versus 1.5% in the gp100 
vaccination alone arm, highly significant contrasts in hazard rates for overall 
survival resulted were detected between the combined arm versus vaccination 
alone (0.68; p < 0.001) and between ipilimumab alone versus vaccination alone 
(0.66; p = 0,003).[44] This information prompted the regard of ipilimumab by 
health authorities for the treatment of advanced melanoma. 
Overall, responses to anti-CTLA4 antibodies seem to be durable, yet may take 
the length of 12 weeks or much more to develop and late-onset objective 
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reactions are sometimes preceded by months of stable illness or even transient 
sickness progression. Side effects with CTLA4 barricade are autoimmune-
related, however less intense than those detected with exogenous cytokine 
therapy and are controllable.[44] Most common side effects include diarrhea and 
rash.[43, 44] 
1.8.2 MAPK Signaling and Inhibitors 
On the upstream level of receptor tyrosine kinases, 30% to 40% of the acral and 
mucosal melanomas and melanomas from chronically sun-exposed skin harbor 
activating mutations or copy number amplifications of the KIT gene.[19] Most 
frequently affected by constitutively activating mutations are in about 15% to 20% 
the NRAS gene and in 50%-60% the BRAF gene.[45] 
Interestingly, the frequency of BRAF mutations is high in melanomas from 
intermittently UV exposed skin, yet low in melanomas with histopathologic signs 
of high UV damage to the skin,[19, 45] i.e. with increasing amounts of mutagenic 
UV radiation the BRAF mutation frequency drops. 
Vemurafenib formerly also known as RG7204 or PLX4032 is a selective inhibitor 
of the oncogenic V600E mutant BRAF kinase. With evaluated response rates 
ranging between 60% and 88%, Vemurafenib represents a therapeutic milestone 
in melanoma patients since decades [3-5]. Patients with solid tumors carrying the 
V600E mutation showed an improvement up to 70% after phase I dose escalation 
study according to ASCO 2009.[46] These promising data was confirmed in the 
consecutive phase II trial including 132 patients with metastatic melanoma 
carrying a BRAF V600 mutation.[47] The overall response rate in that trial was 
53% while the median duration of response, the median progression-free survival 
and the overall median survival  were reported to be 6.7, 6.8 and 15.9 months, 
respectively.[47] Moreover, an increase in overall survival up to 14 months 
compared to 9 months with standard dacarbazine treatment was reported 
whereas some patients are still under treatment after 2 years.[6] 
According to the Data which was released in 2011 from the phase III registration 
trial, 675 patients were randomly assigned to receive vemurafenib (960mg p.o. 
bid) or dacarbazine (1000/m2 i.v. every 3 weeks). [48] After 6 months, overall 
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survival was superior in the vemurafenib group compared to the dacarbazine 
cohort (84% vs. 64%). The hazard ratio for death in the vemurafenib group was 
0.37 (p<0.001). 
Response rates were 48% for the vemurafenib and 5% for the dacarbazine 
treatment arm. In an updated analysis, median overall survival rates for 
vemurafenib and DTIC treated patients were 13.2 months and 9.6 months, 
respectively.[49] In this updated analysis hazard ratios for progression free and 
overall survival were rendered to be 0.38 (p<0.001) and 0.70 (p<0.001), 
respectively. 
Other BRAF inhibitors such as dabrafenib and encorafenib are likewise in clinical 
routine or trials. Recently, data from another registration phase III trial comparing 
dabrafenib and dacarbazine was published [50]. In this trial, 250 BRAF-(V600E) 
patients were randomly assigned to receive either dabrafenib 150 mg twice daily 
p.o. (187 patients) or dacarbazine 1000/m2 i.v. every 3 weeks (63 patients). 
Median progression-free survival was 5.1 months for dabrafenib and 2.7 months 
for dacarbazine, hazard ratio 0.30 (p<0.0001). Most common observed adverse 
events in the dabrafenib arm were skin-related toxic effects, fever, fatigue, 
arthralgia, and headache. 
1.9 Aims of this Evaluation 
Patients under vemurafenib treatment normally receive CT staging every 6-12 
weeks, resulting in 8-16 CT examinations in two years. The potential risk of 
sequential CT scans to induce cancer is still controversially discussed. In a recent 
analysis the risk is numbered to be 0.7% which seems to be low, however 
approximately 29,000 cancers could be related to CT scans in the USA every 
year.[51] With increasing overall survival time due to effective treatments the 
reduction of life time radiation and CT scans should also be considered in stage 
IV melanoma patients. 
In this evaluation we were interested in whether S100B and LDH are able to 
monitor and predict objective tumor responses and tumor progression of 
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vemurafenib treated patients. Radiologic measurements according to RECIST 
were taken as gold standard for monitoring patient's course of the disease. 
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oxidation method of lactate to pyruvate with simultaneous reduction of 
nicotinamide adenine dinucleotide (NAD+) to NADH and H+ at a pH of 8.55. The 
change in absorption is measured at 340 nm and considered as proportional to 
LDH activity. 
2.1.3 Radiological Evaluation 
All patients received contrast-enhanced CT scans of the brain, head & neck, 
thorax and abdominal region before start of vemurafenib treatment. Target 
lesions were defined according to RECIST V1.1 and followed up during regular 
staging evaluations. RECIST 1.1 defined criteria were used to determine 
complete response, partial response, stable and progressive disease: 
2.1.3.1 Evaluation of Target Lesions 
2.1.3.1.1 Complete Response (CR) 
 Disappearance of all target lesions. 
 Any pathological lymph nodes (whether target or non-target) must have 
lessening in short axis to <10 mm. 
2.1.3.1.2 Partial Response (PR) 
 At minimum a 30% reduction in the sum of diameters of target lesions, 
taking as reference the baseline sum diameters. 
2.1.3.1.3 Progressive Disease (PD) 
 At least a 20% increment in the sum of diameters of target lesions, taking 
as reference the smallest sum on study (this includes the baseline sum if 
that is the smallest on study). Notwithstanding the relative increment of 
20%, the whole must likewise exhibit a flat out expansion of no less than 
5 mm. (Note: the appearance of one or more new lesions is likewise 
considered progression). 
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2.1.3.1.4 Stable Disease (SD) 
 Neither sufficient shrinkage to qualify for PR nor sufficient growth to qualify 
for PD, The smallest diameters was taken as reference while on study. 
2.1.3.2 Evaluation of Non-Target Lesions 
2.1.3.2.1 Progressive Disease (PD) 
 Unequivocal progression of existing non-target lesions. (Note: the 
existence of one or more new lesions is also considered progression). 
All patients had to have unresectable stage III or VI melanoma and were tested 
to carry the BRAF V600E mutation using the Roche Cobas Assay or by analysing 
tumor tissue by conventional Sanger sequencing. Cobas tests were performed at 
Targos Molecular Pathology GmbH, Kassel, Germany. 
 
2.1.3.2.2 Complete Response (CR) 
 Disappearance of all non-target lesions and normalisation of tumour 
marker level. All lymph nodes have to be non-pathological in size (<10 mm 
short axis) 
2.1.3.2.3 Non-CR / Non-PD 
 Persistence of one or more non-target lesion(s) and/or maintenance of 
tumour marker level over the standard limits. 
2.1.4 Statistics 
R 2.15.2 [52] with the package “caret”[53] was used for all statistical analyses. 
Figures were plotted using ggplot2 Version 0.95.[54] Accuracy values for 
predicting RECIST confirmed tumor response and S100B/LDH with 95% 
confidence intervals were calculated. Correlation was also evaluated using 
Spearman's rank correlation [rho]. Additionally, polynominal regression models 
(linear, quadratic and cubic) were established and compared via ANOVA. For all 
statistical tests a p-value of 0.05 was considered to describe a significant result. 
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Table 3-1 Patient characteristics at baseline 
Age (Years) 
Mean 
Range 
 
53 
29-77 
Sex (n) 
Female 
Male 
 
19, 43% 
25, 57% 
Histological type (n) 
Nodular 
Superficial spreading 
Acrolentiginous 
unknown primary origin 
 
16, 36% 
16, 36% 
4, 9% 
8, 18% 
Localization of the primary melanoma (n) 
Head 
Neck 
Back 
Trunk 
Upper extremity 
Lower extremity 
 
1, 2% 
1, 2% 
11, 25% 
7, 16% 
2, 5% 
14, 32% 
Ulceration 
Present 
Absent 
Unknown 
 
12, 27% 
10, 22% 
22, 50% (8 cases with no primary 
melanoma) 
Tumor thickness (mm) 
Mean 
Range 
 
3.4mm according to Breslow 
0.55mm-17mm 
Line of therapy (n) 
First 
Second 
 
20, 45% 
24, 55% 
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Table 3-2 Accuracy and regression models for correlation between RECIST and S100/LDH 
  
RECIST vs 
S100B 
RECIST vs 
S100B 
evaluated at 
baseline 
RECIST vs 
LDH 
RECIST vs 
LDH evaluated 
at baseline 
Accuracy 
 
63.6% 
95% CI: 
(47.8, 77.6) 
 
81.2% 
95% CI: 
(63.6, 92.8) 
 
61.4% 
95% CI: 
(45.5, 75.6) 
 
85.7% 
95% CI: 
(63.7, 97.0) 
Linear model p=0.404 p=0.445 p=0.0714 p=0.0831 
Quadratic model p=0.356 p=0.706 p=0.0868 p=0.17 
Cubic model p=0.259 p=0.326 p=0.132 p=0.211 
ANOVA 
 
linear vs. 
quadratic 
Pr(>F): 0.24 
linear vs. cubic 
Pr(>F): 0.16 
 
linear vs. 
quadratic 
Pr(>F): 0.72 
linear vs. cubic 
Pr(>F): 0.10 
 
linear vs. 
quadratic 
Pr(>F): 0.20 
linear vs. cubic 
Pr(>F): 0.38 
 
linear vs. 
quadratic 
Pr(>F): 0.43 
linear vs. cubic 
Pr(>F): 0.32 
 
3.3 Progression and Correlation with S100B and LDH 
Overall, 36 out of 44 patients had progressive disease. At time point of RECIST-
confirmed progression 14 patients had increased levels above ULN for LDH and 
23 patients had pathologic levels of S100B. Eight patients had both, increased 
serum S100B values and elevated LDH levels at the same time. 19 patients were 
judged to have progressive disease because of increased target lesions whereas 
the other 19 patients had new lesions at time point of progression. 
The accuracy to predict progression was 30.3% for S100B and 32.4% for LDH. 
For patients with increased values at baseline the accuracy rates were 26.9% for 
S100B and 21.1% for LDH (Table 3-3). After constructing the polynomial 
regression models for S100B evaluated at baseline, LDH and LDH evaluated at 
baseline indicated significant p-values for linear, quadratic and cubic evaluations, 
however, all of them failed in the ANOVA analysis. 
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Table 3-3 Accuracy and regression models for correlation between RECIST and S100/LDH 
  
RECIST vs 
S100B 
RECIST vs 
S100B 
evaluated at 
baseline 
RECIST vs 
LDH 
RECIST vs 
LDH evaluated 
at baseline 
Accuracy 
 
30.3% 
95% CI: 
(15.6, 48.7) 
 
26.9% 
95% CI: 
(11.6, 47.8) 
 
32.4% 
95% CI: 
(17.4, 50.5) 
 
21.1% 
95% CI: 
(6.1,45.6) 
Linear model p=0.476 p=0.0382 p=0.0286 p=0.036 
Quadratic model p=0.687 p=0.0394 p=0.0294 p=0.0131 
Cubic model p=0.372 p=0.0416 p=0.024 p=0.0229 
ANOVA 
 
linear vs. 
quadratic 
Pr(>F): 0.61 
linear vs. cubic 
Pr(>F): 0.13 
 
linear vs. 
quadratic 
Pr(>F): 0.13 
linear vs. cubic 
Pr(>F): 0.18 
 
linear vs. 
quadratic 
Pr(>F): 0.12 
linear vs. cubic 
Pr(>F): 0.12 
 
linear vs. 
quadratic 
Pr(>F): 0.039 
linear vs. cubic 
Pr(>F): 0.297 
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Figure 3-5 Patient 1 - Pulmonary metastasis at baseline 
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Figure 3-6 Patient 1 - Complete response: Disappearance of pulmonary metastasis after eight weeks of 
treatment, only small remnants visible 
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Figure 3-7 Patient 1 - Progressive disease: Progression of pulmonary metastasis at week 48 
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Figure 3-8 Patient 2 - Multiple soft tissue metastases of the right breast at baseline 
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Figure 3-9 Patient 2 - Partial repose after 20 weeks of treatment, still multiple soft tissue 
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Figure 3-10 Patient 2 - Progressive disease after 24 weeks of treatment of the right breast; 
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Figure 3-11 Patient 3 - Single pulmonal lymph node metastasis at baseline 
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Figure 3-12 Patient 3 - Complete response after 36 weeks of treatment 
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Figure 3-13 Patient 3 - Continuing complete response after 72 weeks of treatment 
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Figure 3-14 Patient 4 - Lymph node metastasis of the right axilla 
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Figure 3-15 Patient 4 - Partial repose after twenty weeks of treatment, still measurable lymph 
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Figure 3-16 Patient 4 - Late complete response after 54 weeks of treatment 
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Figure 3-17 Spider plot of the course of target lesions measured by the RECIST criteria. CT, computed 
tomography; RECIST, Response Evaluation Criteria in Solid Tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
Figure 3-18 Spider plot of the course of S100B. 
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Figure 3-19 Spider plot - course of S100B for those patients with S100B above ULN at baseline. 
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Figure 3-20 Course of S100B levels (logarithmic y-scale). Rug indicates course of action (treatment 
continued, treatment stopped due to progressive disease, patients still under treatment at end of 
evaluation period 
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Figure 3-21 Course of S100B levels for patients with S100B above ULN at start of treatment (logarithmic 
y-scale). Rug indicates course of action (treatment continued, treatment stopped due to progressive disease, 
patients still under treatment at end of evaluation period) 
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Figure 3-22 Spider plot of the course of LDH. 
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Figure 3-23 Spider plot - course of LDH for those patients with LDH above ULN at baseline. 
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Figure 3-24 Course of LDH levels (logarithmic y-scale). Rug indicates course of action (treatment 
continued, treatment stopped due to progressive disease, patients still under treatment at end of evaluation 
period 
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Figure 3-25 Course of LDH levels for patients with LDH above ULN at start of treatment (logarithmic y-
scale). Rug indicates course of action (treatment continued, treatment stopped due to progressive disease, 
patients still under treatment at end of evaluation period 
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S100B and LDH however did not correlate in most of those cases either. Another 
explanation which is likely for S100B is that the tumor loses its ability to secret 
S100B because of dedifferentiation.[58]. 
In a recently published report by Sanmamed and colleagues S100B as well as 
the serum protein melanoma-inhibitory-activity (MIA) were evaluated in terms of 
their reliability as tumor markers for the treatment of metastatic melanoma with 
vemurafenib. In contrast to our study, S100B was also judged as good marker to 
detect tumor progression [59]. One explanation for this difference might be the 
radiologic evaluations. Whereas in our cohort the extent of the disease was 
measured according to RECIST regularly, the progression in the cohort of 
Sanmamed et al. was judged clinically. 
Looking at our polynomial models it seems that there is a correlation for S100B 
evaluated at baseline, LDH, LDH evaluated at baseline with tumor progression. 
However, in the ANOVA evaluation no model was superior in comparison to the 
others. 
Lactate dehydrogenase is stated pervasively in different healthy tissues. Elevated 
serum concentrations of the intracellular enzyme are mainly a result of cell lysis. 
Moreover, increased serum LDH levels occur in different tumor entities and 
indicate a high turn-over of tumor cells and also necrosis in fast-growing tumors. 
Increased LDH values are associated with high tumor burden and seem to be 
particularly elevated in liver metastases for which the reason is not known.[60-
62] 
S100B is tissue specific and expressed by glial cells of the brainS100B and LDH 
seem to predict tumor response with acceptable accuracy in early stages of the 
disease, especially for those patients with increased S100B and LDH levels at 
baseline. In this early phase of the disease CT scan intervals could be prolonged 
or scans could maybe omitted completely to reduce the radiation exposure 
without missing tumor progression. For detecting tumor progression in later 
phases of the disease both markers cannot substitute CT scans because of their 
inacceptable accuracy rates, melanocytes, and other cell types, which are 
derived from the neural crest. Moreover, it is perceptible in dendritic and 
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chondrocytes cells. Most melanomas strongly express S100B, however a 
complete lack of S100B expression can be observed by immunohistochemistry 
in a small proportion of melanoma patients.[63] In cell culture experiments it was 
shown that S100B is released upon metabolic stress [64] and it is likewise 
elevated in patients with neural diseases showing metabolic abnormalities like 
schizophrenia or depression.[65] However, cell death seems to be the major 
cause for elevated S100B levels.[66] 
In conclusion, S100B and LDH seem to predict tumor response with acceptable 
accuracy in early stages of the disease, especially for those patients with 
increased S100B and LDH levels at baseline. In this early phase of the disease 
CT scan intervals could be prolonged or scans could maybe omitted completely 
to reduce the radiation exposure without missing tumor progression. For 
detecting tumor progression in later phases of the disease both markers cannot 
substitute CT scans because of their inacceptable accuracy rates. 
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Appendix B: The concentration of serum LDH 
Table B- 1 The Concentration of Serum LDH according to the stage and disease activity 
patient no Base line stage 1 
stage 
2 
stage 
3 
stage 
4 
stage 
5 
stage 
6 
stage 
7 
1 191 240 224 177     
2 239 109 212      
3 185 183 232 194     
4 419 235 266      
5 317 256       
6 271 242 210      
7 887 248 334      
8 160 170 181 195     
9 790 353       
10 213 201 217 231 218    
11 458 226 207 190     
12 206 204 200 212 210    
13 187 199 259      
14 253 281 205      
16 197 227 226 207     
19 173 175 160 182     
20 237 171 198 178     
21 585 163 259      
22 401 231 204 256 235    
23 670 170 195 230     
24 230 326       
25 294 190       
26 191 221       
27 1064 561 209      
28 157 174 182      
29 245 374 274 447     
30 217 209 191 202 197    
31 191 156 167 167 156    
32 174 229       
33 178 172 194      
34 176 276 255      
35 327 255 226      
36 259 187 180      
37 3177 399 600      
38 317 211 229      
5615 206 201 224 216 209 213 220 217 
5614 312 192 244 194 215    
5613 209 185 176      
5610 408 183 190 213     
5609 170 197 163      
5608 448 317 173      
5607 330 344 260 212 263 217 239 191 
5602 213 229 278 211 232 235 212 245 
5606 330 344  212 263 217 239  
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Appendix C: RECIST value for each stage 
Table C- 1 RECIST value for all patients at each stage 
PAT_ID  baseline Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Stage 6 Stage 7 Stage 8 Stage 9 
5610 27,250 24,230 18,260 16,240 14,100           
5609 32,730 19,490 10,570               
5608 69,640 62,700                 
5607 30,690 19,980 20,240 18,720 17,350 17,860 14,420 7,740 7,160 5,230 
5606 158,500 84,160 60,790 68,170 61,210 60,290 57,200       
5602 51,710 28,840 13,920 17,820 11,48 15,54 11,61 7,3 7,11   
5613 26,370 15,640 9,750 9,950             
5614 29,340 19,310 19,990 15,980             
5615 10,760 5,820 4,650 6,050 0,000 0,000   0,000 0,000 0,000 
1 11,980 7,350 5,830 6,25             
2 96,030 81,970 84,830               
3 73,380 75,160 75,840 75,5             
4 59,250 44,310 41,540               
5 15,750 5,190                 
6 70,250 54,250 49,510               
7 85,320 61,190 66,790               
8 43,720 19,790 24,740 21,4             
9 186,130 119,700 153,770               
10 38,920 24,120 15,280 17,2             
11 137,200 103,170 71,490 69,98             
12 52,110 31,830 27,840 17,010 16,94           
13 41,760 27,790 22,750               
14 72,240 54,810 69,240               
15                     
16 27,310 16,990 0,000 0,000             
17                     
18                     
19 6,280 0,000 0,000               
20 70,270 63,620 79,480               
21 66,490 54,330 46,980               
22 27,150 14,210 12,440 20,93             
23 34,130 27,450 20,92               
24 32,210 21,570 19,030               
25 26,940 15,860 15,190               
26 82,770 63,000 56,010               
27 179,370 148,160 161,410               
28 23,460 21,770 13,38               
29 61,920 33,390 50,400               
30 49,580 9,290 0,000 0,000 27,94           
31 43,660 41,520 42,310 40,450 46,51           
32 169,330 72,880 67,270               
33 37,880 22,590 35,63               
34 11,500 9,850 11,000               
35 63,450 42,090 42,32               
36 55,240 28,540 16,25               
37 51,220 41,370 24,27              
38 17,310 12,980 9,520 6,93       
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Appendix D: Regression Models correlation before first stage 
 
Table D- 1 Accuracy and regression models for correlation between RECIST and S100/LDH from start of 
therapy till first staging. 
Parameter S100B S100B evaluated at baseline LDH 
LDH evaluated at 
baseline 
Accuracy 
63.60% 81.20% 61.40% 85.70% 
95% CI : (47.8, 
77.6) 95% CI : (63.6, 92.8) 
95% CI : (45.5, 
75.6) 95% CI : (63.7, 97.0) 
Linear model p=0.404 p=0.445 p=0.0714 p=0.0831 
Quadratic model p=0.356 p=0.706 p=0.0868 p=0.17 
Cubic model p=0.259 p=0.326 p=0.132 p=0.211 
ANOVA 
linear vs. quadratic 
Pr(>F): 0.24 
linear vs. quadratic 
Pr(>F): 0.72 
linear vs. quadratic 
Pr(>F): 0.20 
linear vs. quadratic 
Pr(>F): 0.43 
linear vs. cubic 
Pr(>F): 0.16 
linear vs. cubic 
Pr(>F): 0.10 
linear vs. cubic 
Pr(>F): 0.38 
linear vs. cubic 
Pr(>F): 0.32 
 
